Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 20,633 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blood sample Clear all
Completed Phase 1 Interventional

Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer

NCT04121676
View directory record Official record
Conditions
Advanced Cancer
Interventions
AGEN2373, Botensilimab
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Coral Gables, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 19, 2026, 4:49 PM EDT
Completed Phase 3 Interventional Results available

An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer

NCT02632409
View directory record Official record
Conditions
Various Advanced Cancer
Interventions
Nivolumab, Placebo
Biological · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
709 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
33
States / cities
Anchorage, Alaska • Tucson, Arizona • Clovis, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 19, 2026, 4:49 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy

NCT03457493
View directory record Official record
Conditions
Parkinson Disease
Interventions
DPA-714-PET/MRI, 5-year Follow-up DPA-714-PET/MRI, DPA-714 Metabolite Analysis
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
30 Years and older
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 19, 2026, 4:49 PM EDT
Terminated Not applicable Interventional Results available

Endurant Evo US Clinical Trial

NCT02393716
View directory record Official record
Conditions
Abdominal Aortic Aneurysm, AAA
Interventions
Endurant Evo AAA Stent Graft System, Endovascular aneurysm repair (EVAR)
Device · Procedure
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
14
States / cities
San Diego, California • Stanford, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Oct 19, 2026, 4:49 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation

NCT00415506
View directory record Official record
Conditions
Scleritis, Orbital Disease
Interventions
Rituximab
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 16, 2013 · Synced Oct 19, 2026, 4:49 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Feasibility Study of PID Versus MPC and HMS

NCT01987206
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
MPC control algorithm, PID control algorithm
Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2016 · Synced Oct 19, 2026, 4:49 PM EDT
Completed Phase 1 Interventional

Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

NCT03036904
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
Interventions
Venetoclax, Rituximab, Etoposide, Vincristine Sulfate, Cyclophosphamide, Prednisone, Doxorubicin Hydrochloride
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
6
States / cities
Boston, Massachusetts • St Louis, Missouri • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 19, 2026, 4:49 PM EDT
Completed Phase 2 Interventional Results available

Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus

NCT00076752
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
fludarabine phosphate, cyclophosphamide, Rituxan (rituximab), filgrastim, methylprednisolone, immunologic technique, laboratory biomarker analysis, autologous hematopoietic stem cell transplantation, Diphenhydramine, Mesna
Drug · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years to 40 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 19, 2026, 4:49 PM EDT
Completed No phase listed Observational

Psychological, Psychophysical and Epigenetic Determinants of Chronic Pain After Cytoreductive - Hyperthermic Intraoperative Chemotherapy

NCT05083338
View directory record Official record
Conditions
Appendix Carcinoma, Carcinomatosis, Colorectal Carcinoma, Gastric Carcinoma, Malignant Peritoneal Neoplasm, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Pain Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Oct 19, 2026, 4:49 PM EDT
Completed Phase 4 Interventional Results available

An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate

NCT02187055
View directory record Official record
Conditions
Rhematoid Arthritis
Interventions
Tofacitinib with methotrexate, Tofacitinib without methotrexate, Adalimumab with methotrexate
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
60
States / cities
Huntsville, Alabama • Gilbert, Arizona • Covina, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 19, 2026, 4:49 PM EDT
Completed Phase 2 Interventional Results available

Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia

NCT00250926
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Bortezomib, Dexamethasone, Rituximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 19, 2026, 4:49 PM EDT
Terminated No phase listed Observational

Evaluating the Effects of EECP on Circulation, Blood Glucose Level and Blood Pressure in Type 2 Diabetes Mellitus

NCT02040025
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Not listed
Lead sponsor
David Grant U.S. Air Force Medical Center
Federal
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Travis Air Force Base, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 19, 2026, 4:49 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

ROTEM® Sigma Performance Evaluation - Method Comparison With Predicate Device and Reference Intervals

NCT02379104
View directory record Official record
Conditions
Blood Coagulation Disorders
Interventions
ROTEM sigma
Device
Lead sponsor
Tem Innovations GmbH
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Orlando, Florida • Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 19, 2026, 4:49 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Oncology Associated Symptoms & Individualized Strategies

NCT03122249
View directory record Official record
Conditions
Advanced Cancer
Interventions
Advanced Cancer Symptom Management
Behavioral
Lead sponsor
Stephanie Gilbertson-White
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Fairfield, Iowa
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 19, 2026, 4:49 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging

NCT00606138
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
ranibizumab, Laser photocoagulation
Drug · Procedure
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 19, 2026, 4:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Computerized Health Education to Promote Physical Activity

NCT00242658
View directory record Official record
Conditions
Hypertension
Interventions
Tailored Physical Activity Intervention
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
394 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 12, 2012 · Synced Oct 19, 2026, 4:49 PM EDT
Completed Phase 2 Interventional

Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma

NCT00074178
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, pegfilgrastim, cyclophosphamide, cytarabine, dexamethasone, etoposide phosphate, methotrexate
Biological · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
16 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 19, 2026, 4:49 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Glycemic Index of Commonly Consumed Sweeteners

NCT02931578
View directory record Official record
Conditions
Healthy
Interventions
Glucose100, Glucose50, Glucose42, Oral Glucose Tolerance Test
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 19, 2026, 4:49 PM EDT
Active, not recruiting Phase 1 Interventional

Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours

NCT04735978
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
RP3, Nivolumab
Biological
Lead sponsor
Replimune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Iowa City, Iowa • Pittsburgh, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 19, 2026, 4:49 PM EDT
Terminated Phase 3 Interventional

Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery

NCT00338585
View directory record Official record
Conditions
Arterial Occlusive Diseases
Interventions
alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 19, 2026, 4:49 PM EDT
Active, not recruiting Phase 1 Interventional

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

NCT02160015
View directory record Official record
Conditions
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Electrocardiogram, Ibrutinib, Lenalidomide, Magnetic Resonance Imaging, Rituximab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 19, 2026, 4:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Individually Tailored Web-Based Program to Improve Blood Pressure Control

NCT00377208
View directory record Official record
Conditions
Hypertension
Interventions
Web-Based Intervention
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
21 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 19, 2026, 4:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Identifying Body Awareness-related Brain Network Changes During Cognitive Multisensory Rehabilitation for Reduced Neuropathic Pain in People With Spinal Cord Injury

NCT04706208
View directory record Official record
Conditions
Spinal Cord Injuries, Neuropathic Pain
Interventions
Cognitive Multisensory Therapy, Usual Care, Clinical Assessment, Magnetic Resonance Imaging (MRI), OPTIONAL: blood draw
Behavioral · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 19, 2026, 4:49 PM EDT
Completed No phase listed Observational

Prostate Biomarker Study

NCT00574899
View directory record Official record
Conditions
Prostate Cancer
Interventions
Questioners, blood specimens, prostate tissue specimens
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
35 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Oct 19, 2026, 4:49 PM EDT